Get to know our clinical trials
Phase II platform clinical trial of precision immuno-oncology with tumor agnostic indication for specific somatic mutations (tapistry).
THE PURPOSE OF THIS STUDY IS TO COMPARE THE EFFECTS, POSITIVE OR NEGATIVE, OF CERTAIN TARGETED TREATMENTS OR IMMUNOTHERAPIES (DRUGS THAT HELP THE BODY'S IMMUNE SYSTEM FIGHT CANCER CELLS) IN PATIENTS WHO HAVE SOLID TUMORS WITH SPECIFIC GENETIC ALTERATIONS OR A HIGH NUMBER OF MUTATIONS. PATIENTS WILL BE ASSIGNED TO DIFFERENT COHORTS (GROUPS) BASED ON THE PRESENCE OF A SPECIFIC TYPE OF GENETIC ALTERATION OR A HIGH NUMBER OF MUTATIONS IN THE TUMOR.
- PHASE II PLATFORM CLINICAL TRIAL OF PRECISION IMMUNO-ONCOLOGY WITH TUMOR AGNOSTIC INDICATION FOR SPECIFIC SOMATIC MUTATIONS (TAPISTRY).
- Code EudraCT: 2020-001847-16
- Protocol number: BO41932
- Promoter: Roche Farma, S.A.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.